CD160 and B-cell chronic lymphocytic leukemia: The poor CAR-T therapeutic effect in CLL may be caused by the abnormal upregulation of depletion indicators (including PD1, CD244, and CD160) on T cell surface, the lack of memory cells, and the low proliferation and cytotoxicity of CD8-positive T cells in CLL patients [68, 69].